A new tool in the battle against Alzheimer's disease and aging: Ex vivo gene therapy

Rejuvenation Research

Volumn 8, Issue 3, 2005, Pages 131-134

  Ebert, Allison D ^a   Svendsen, Clive N ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NERVE GROWTH FACTOR; PROTEIN TYROSINE KINASE A;

AGING; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN CORTEX; CELL SURVIVAL; CHOLINERGIC SYSTEM; DEMENTIA; FOREBRAIN; GENE THERAPY; HUMAN; INNERVATION; MEMORY; NERVE PROJECTION; NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW;

AGING; ALZHEIMER DISEASE; GENE THERAPY; HUMANS; NERVE GROWTH FACTOR;

EID: 24944536068     PISSN: 15491684     EISSN: None     Source Type: Journal    
DOI: 10.1089/rej.2005.8.131     Document Type: Review

References (15)

1. Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, Patel P, Blesch A, Vahlsing HL, Ho G, Tong G, Potkin SG, Fallon J, Hansen L, Mufson EJ, Kordower JH, Gall C, Conner J. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005;11(6):551-555.
2. Fischer W, Wictorin K, Bjorklund A, Williams, LR, Varon S, Gage FH. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 1987;329(6134):65-68.
3. Conner JM, Darracq MA, Roberts J, Tuszynski MH. Nontropic actions of neurotrophins: subcortical nerve growth factor gene delivery reverses age-related degeneration of primate cortical cholinergic innervation. Proc Natl Acad Sci USA 2001;98(4):1941-1946.
4. Mayeux R, Sano M. Treatment of Alzheimer's disease. N Engl J Med 1999;341(22):1670-1679.
5. Eriksdotter Jonhagen M, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B, Olson L, Seiger, Shigeta M, Theodorsson E, Viitanen M, Winblad B, Wahlund LO. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 1998;9(5): 246-257.
6. Tuszynski MH. Growth-factor gene therapy for neurodegenerative disorders. Lancet Neurol 2002;1(1): 51-57.
7. Emerich DF, Winn SR, Harper J, Hammang JP, Baetge EE, Kordower JH. Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: rescue and sprouting of degenerating cholinergic basal forebrain neurons. J Comp Neurol 1994;349(1): 148-164.
8. Lin Q, Cunningham LA, Epstein LG, Pechan PA, Short MP, Fleet C, Bohn MC. Human fetal astrocytes as an ex vivo gene therapy vehicle for delivering biologically active nerve growth factor. Hum Gene Ther;1997;8(3):331-339.
9. Albeck D, Mesches MH, Juthberg S, Browning M, Bickford PC, Rose GM, Granholm AC. Exogenous NGF restores endogenous NGF distribution in the brain of the cognitively impaired aged rat. Brain Res 2003;967(1-2):306-310.
10. Mufson EJ, Ma SY, Cochran EJ, Bennett DA, Beckett LA, Jaffar S, Saragovi HU, Kordower JH. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 2000;427(1):19-30.
11. Gilmor ML, Erickson JD, Varoqui H, Hersh LB, Bennett DA, Cochran EJ, Mufson EJ, Levey AI. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 1999;411(4):693-704.
12. Lum JJ, Bauer DE, Kong M, Harris MH, Li C, Lindsten T, Thompson CB. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005;120(2):237-248.
13. Hagg TM, Manthorpe M, Vahlsing HL, Varon S. Delayed treatment with nerve growth factor reverses the apparent loss of cholinergic neurons after acute brain damage. Exp Neurol 1988;101(2):303-312.
14. Tai YT, Svendsen CN. Stem cells as a potential treatment of neurological disorders. Curr Opin Pharmacol 2004;4(1):98-104.
15. Klein SM, Behrstock S, McHugh J, Hoffmann K, Wallace K, Suzuki M, Aebischer P, Svendsen CN. GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum Gene Ther 2005;16(4):509-521.